Company file

Identity

MEDESIS PHARMA

Medesis Pharma is a Pharmaceutical Biotechnology company whose products and programs in development are based on drug delivery technology allowing, after oral administration, a plasma transport protected in HDL lipoproteins and an intra-cellular delivery of water-soluble pharmaceutical active ingredients: metal ions, as well as biological molecules such as oligonucleotides and peptides, with a passage of BBB.

4 products are starting clinical phases 2 in 2021 - NanoManganese® for the prevention and treatment of severe forms of COVID-19 - NanosiRNA® COVID to inhibit the replication of the coronavirus responsible for COVID-19 - NanosiRNA® HD for the treatment of Huntington's disease - NanoLithium® for the treatment of Alzheimer's disease Partnerships are also underway to inhibit gene expression in oncology with siRNAs